Search results
28 lut 2021 · Pharmacological and non-pharmacological management of MI. Monitoring and Review. Recognising myocardial infarction. Risk factors and complications of MI.
Andrew Civitello, M.D. Associate Professor, Baylor College of MedicineMedical Director, Heart Transplant ProgramCo-Director, Advanced Heart Failure CenterDir...
6 lip 2021 · Furthermore, MRA treatment is recommended in patients with AMI with systolic heart failure defined as left ventricular ejection fraction ≤40%. 6 This recommendation is mainly based on the results of the EPHESUS (Eplerenone Post‐AMI Heart Failure Efficacy and Survival) trial (published in 2003) demonstrating improved mortality at 30‐days ...
17 lut 2020 · Patients should remain on dual antiplatelet therapy post-MI. ASA, ticagrelor, clopidogrel, and prasugrel all have mortality benefit post-MI. Optimal duration: STEMI or NSTEMI: At least 1 year (CCS) Elective PCI (Outpatient): At least 6mo (CCS) There is evidence to continue >1 year.
9 maj 2023 · Guideline‐based optimal medical therapy (OMT) for patients with acute myocardial infarction consists of antiplatelet therapy, angiotensin‐converting enzyme inhibitors/angiotensin II receptor blockers, β‐blockers, and statins.
guideline on secondary prevention after an MI. 1 This article summarises the most recent recommendations from the National Institute for Health and Care Excellence (NICE). 2
It is reported that women with acute MI under the age of 50 years were less likely to undergo coronary revascularization and be treated with guideline-directed medical therapies irrespective of SCAD, leading to poor prognosis . Further studies are needed to clarify the underlying mechanisms and develop novel therapeutic strategies for patients ...
